🧪 The CMPC is part of the Canadian Critical Drug Initiative (CCDI) to strengthen the pharmaceutical supply chain.
🏭 The facility will have the capacity to produce over 70 million doses per year and fill Canada’s needs in less than 100 days.
💊 Benefits include improved patient access to medicines and increased capacity for therapeutic drug production.
💰 The CCDI investment includes funding from the federal government, the Government of Alberta, and City of Edmonton.
Introduction:
Applied Pharmaceutical Innovation (API) and the University of Alberta’s Li Ka Shing Applied Virology Institute have begun construction on the Critical Medicines Production Center (CMPC). The facility is part of the Canadian Critical Drug Initiative (CCDI) and aims to secure supply chain resilience in the pharmaceutical industry and position Canada as a leader in the field.
- The CMPC is an 83,000+ ft2 facility that will have the capacity to produce over 70 million doses of a product per year.
- The Center aims to enhance patient access to vital medicines, improve hospital operations, and expand the capability to produce therapeutic drugs.
- The CMPC is a significant contributor to Alberta’s biomanufacturing and life sciences sector, creating over 350 jobs in the province.
- The project received funding from the federal government, the Government of Alberta, and approval from the City of Edmonton.
- Construction is expected to be completed by 2026.
Conclusion:
The establishment of the Critical Medicines Production Center in Alberta is a crucial step in securing Canada’s pharmaceutical supply chain and positioning the country as a leader in the industry. The facility’s advanced capabilities and the creation of jobs in the biomanufacturing sector will enhance patient access to critical medications and contribute to the overall growth of the life sciences industry in Alberta.
